Please ensure Javascript is enabled for purposes of website accessibility

Why Catamaran's Loss Could Be Long-Term Investors' Gain

By Dave Williamson – Feb 27, 2014 at 10:03PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The market sold off Catamaran today, which could make the pharmacy benefit manager a great buy for long-term Foolish investors.

Pharmacy benefit manager Catamaran (CTRX.DL) was the big loser in health care today, with shares falling more than 10% after an earnings report that contained some disappointment. While the company beat on earnings by $0.02 per share and came out handily ahead on the top line, 2014 guidance was the real issue. The company guided for an EPS of $2.04-$2.19 for the year, a big difference from the $2.41 the market was expecting.

However, Motley Fool health-care analyst David Williamson still really likes the company and its use of analytics. In the following video, David gives investors some of the key strengths he sees in the company, and discusses why Obamacare will give this company a strong competitive advantage down the road.

David Williamson has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Catamaran. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Stocks Mentioned

Catamaran Corporation Stock Quote
Catamaran Corporation
CTRX.DL

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.